Cyxone announces that exercise of warrants TO3 amounted to 66% – is allocated 62.4 MSEK
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced a positive outcome of the exercise of warrants of series 3 (TO3). A total of 11,622,863 warrants were exercised, corresponding to approximately 66 percent of all warrants, for subscription of 11,622,863 shares at a subscription price of 5.37 SEK per share. By the exercised warrants, Cyxone is thus allocated approximately 62.4 MSEK before issue costs.Last year, the company carried out a rights issue of units, consisting of a share and a warrant, with the subscription period October 8 to 23, 2018. The exercise period for